(Q50102761)

24 February 2018

title

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. (English)

1 reference

24 February 2018

author name string

Jatinder K Lamba

1

1 reference

24 February 2018

Andrew P Voigt

2

1 reference

24 February 2018

Lata Chauhan

3

1 reference

24 February 2018

Miyoung Shin

4

1 reference

24 February 2018

Richard Aplenc

5

1 reference

24 February 2018

Lisa Eidenschink Brodersen

6

1 reference

24 February 2018

Alan S Gamis

7

1 reference

24 February 2018

Soheil Meshinchi

8

1 reference

24 February 2018

Michael R Loken

9

1 reference

24 February 2018

publication date

10 January 2018

1 reference

24 February 2018

published in

Leukemia & Lymphoma

1 reference

24 February 2018

page(s)

1-4

1 reference

24 February 2018

Consistent quantitative gene product expression: #3. Invariance with age.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1421756

Quantitation of hemopoietic cell antigens in flow cytometry.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29320902

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/10428194.2017.1421756

1 reference

24 February 2018

1 reference

24 February 2018